Malaria Journal

Table 2 Summary of drug interaction in asexual stages of different P. falciparum strains

From: Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization

Drug Combination	P. falciparum strain
Drug Combination	3D7	W2	D6	C2B	IPC-5202	14-B5
DHA–PPQ	Antagonistic	Antagonistic	Antagonistic	Antagonistic	Antagonistic	Antagonistic
CQ–CQ	Additive	Additive	Additive	Additive	Additive	Additive
ATQ–PG	Synergistic	Synergistic	Synergistic	Synergistic	Synergistic	Synergistic
PND–ATQ	Antagonistic	Antagonistic	Antagonistic	Toward Antagonistic	Antagonistic	Antagonistic
MQ–ATQ	Toward Antagonistic	Antagonistic	Toward Antagonistic	Toward Synergistic	Toward Antagonistic	Antagonistic
TQ–ATQ	Toward Synergistic	Toward Antagonistic	Toward Synergistic	Toward Synergistic	Toward Antagonistic	Antagonistic
PND–PG	Toward Antagonistic	Toward Synergistic	Additive	Toward Synergistic	Toward Synergistic	Antagonistic
MQ–PG	Toward Synergistic	Toward Synergistic	Toward Synergistic	Toward Synergistic	Toward Synergistic	Toward Synergistic
TQ–PG	Synergistic	Toward Antagonistic	Toward Synergistic	Toward Synergistic	Additive	Antagonistic

ΣFIC₅₀ (50% Fractional Inhibitory Concentrations), synergism when ΣFIC₅₀ ≤ 0.5; toward synergism when ΣFIC₅₀ < 1; additive when ΣFIC₅₀ = 1; toward antagonism when ΣFIC₅₀ > 1; antagonism when ΣFIC₅₀ ≥ 2 to 4. The values show the mean ± S.D of 3 independent assays for each parasite line
DHA dihydroartemisinin, CQ chloroquine, MQ mefloquine, PPQ piperaquine, ATQ atovaquone, PG proguanil, TQ tafenoquine, PND pyronaridine

Back to article page

ISSN: 1475-2875

Contact us

Submission enquiries: journalsubmissions@springernature.com